Dr. Christopher R. Foss
Claim this profilePresbyterian Intercommunity Hospital
Studies Cancer
Studies Recurrence
4 reported clinical trials
22 drugs studied
Area of expertise
1Cancer
Stage IV
RAF positive
ERK positive
2Recurrence
Stage IV
RAF positive
ERK positive
Affiliated Hospitals
Clinical Trials Christopher R. Foss is currently running
Selumetinib + Olaparib
for Ovarian and Endometrial Cancer
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting1 award Phase 2
Chemotherapy + Binimetinib
for Biliary Tract Cancer
This phase II ComboMATCH treatment trial compares the usual treatment of modified leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) chemotherapy to using binimetinib plus mFOLFOX6 chemotherapy to shrink tumors in patients with biliary tract cancers that have spread to other places in the body (advanced) and had progression of cancer after previous treatments (2nd line setting). Fluorouracil is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It works by killing tumor cells. Leucovorin may help the other drugs in the mFOLFOX6 chemotherapy regimen work better by making tumor cells more sensitive to the drugs. Binimetinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals tumor cells to multiply. This helps to stop or slow the spread of tumor cells. Giving binimetinib in combination with mFOLFOX6 chemotherapy may be effective in shrinking or stabilizing advanced biliary tract cancers in the 2nd line setting.
Recruiting1 award Phase 2
More about Christopher R. Foss
Clinical Trial Related1 year of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Christopher R. Foss has experience with
- Selumetinib Sulfate
- Binimetinib
- Paclitaxel
- Nilotinib Hydrochloride Monohydrate
- Fluorouracil
- Olaparib
Breakdown of trials Christopher R. Foss has run
Cancer
Recurrence
Ovarian Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christopher R. Foss specialize in?
Christopher R. Foss focuses on Cancer and Recurrence. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are RAF positive.
Is Christopher R. Foss currently recruiting for clinical trials?
Yes, Christopher R. Foss is currently recruiting for 3 clinical trials in Whittier California. If you're interested in participating, you should apply.
Are there any treatments that Christopher R. Foss has studied deeply?
Yes, Christopher R. Foss has studied treatments such as Selumetinib Sulfate, Binimetinib, Paclitaxel.
What is the best way to schedule an appointment with Christopher R. Foss?
Apply for one of the trials that Christopher R. Foss is conducting.
What is the office address of Christopher R. Foss?
The office of Christopher R. Foss is located at: Presbyterian Intercommunity Hospital, Whittier, California 90602 United States. This is the address for their practice at the Presbyterian Intercommunity Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.